You are being given a medicine called REGEN-COV (casirivimab and imdevimab) for the treatment or post-exposure prevention of coronavirus disease 2019 (COVID-19).

All formulations and presentations of casirivimab and imdevimab or REGEN-COV distributed under the EUA have expired.

Monoclonal antibodies, such as REGEN-COV, may be associated with worse clinical outcomes when administered to hospitalized patients with COVID-19 requiring high flow oxygen or …

IMPORTANT POSSIBLE SIDE EFFECTS OF REGEN-COV (casirivimab with imdevimab)? Possible side effects of REGEN-COV are: • Allergic reactions. Allergic reactions can happen …

REGEN-COVTM may only be administered in settings in which pharmacists have immediate access to medications to treat severe hypersensitivity reactions, such as anaphylaxis, and the …

May 19, 2021 · Efficacy of REGEN-COV was consistent across subgroups, including patients who were SARS-CoV-2 serum antibody-positive at baseline. REGEN-COV more rapidly reduced …

REGEN-COV (casirivimab and imdevimab) is not authorized for pre-exposure prophylaxis for prevention of COVID-19.